Medexus Pharmaceuticals Inc. (TSE:MDP - Free Report) - Stock analysts at Raymond James dropped their Q3 2026 earnings estimates for Medexus Pharmaceuticals in a note issued to investors on Tuesday, January 7th. Raymond James analyst M. Freeman now expects that the company will post earnings of $0.22 per share for the quarter, down from their prior forecast of $0.24. Raymond James has a "Strong-Buy" rating and a $4.00 price objective on the stock. The consensus estimate for Medexus Pharmaceuticals' current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals' Q4 2026 earnings at $0.23 EPS, FY2026 earnings at $0.89 EPS, FY2027 earnings at $0.88 EPS, FY2028 earnings at $0.80 EPS and FY2029 earnings at $0.77 EPS.
Several other equities research analysts also recently commented on MDP. Alliance Global Partners raised shares of Medexus Pharmaceuticals to a "strong-buy" rating in a report on Monday, December 23rd. Leede Financial set a C$8.25 price target on shares of Medexus Pharmaceuticals and gave the company a "speculative buy" rating in a research note on Monday, September 30th. Two research analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Medexus Pharmaceuticals currently has a consensus rating of "Strong Buy" and an average price target of C$5.25.
View Our Latest Research Report on MDP
Medexus Pharmaceuticals Stock Performance
TSE MDP traded up C$0.47 on Thursday, hitting C$4.07. 130,755 shares of the stock traded hands, compared to its average volume of 74,734. Medexus Pharmaceuticals has a 12 month low of C$1.47 and a 12 month high of C$4.07. The business's fifty day moving average is C$2.74 and its two-hundred day moving average is C$2.52. The firm has a market capitalization of C$99.84 million, a price-to-earnings ratio of 81.40 and a beta of 1.96.
About Medexus Pharmaceuticals
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Featured Articles
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
